Immunome (NASDAQ:IMNM) Trading Up 11.7% - Here's What Happened

Immunome, Inc. (NASDAQ:IMNM - Get Free Report) shares shot up 11.7% on Monday . The stock traded as high as $11.25 and last traded at $12.14. 235,455 shares were traded during mid-day trading, a decline of 76% from the average session volume of 979,078 shares. The stock had previously closed at $10.87.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Stephens assumed coverage on shares of Immunome in a research note on Friday, November 8th. They set an "overweight" rating and a $30.00 target price for the company. Piper Sandler lowered their price objective on Immunome from $23.00 to $21.00 and set an "overweight" rating on the stock in a report on Thursday, November 14th. Finally, Wedbush reiterated an "outperform" rating and set a $33.00 price objective on shares of Immunome in a research report on Monday, January 13th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Immunome currently has a consensus rating of "Buy" and an average target price of $28.60.

Immunome Trading Up 0.3 %

The company has a market capitalization of $832.11 million, a price-to-earnings ratio of -1.29 and a beta of 1.90. The company's 50 day simple moving average is $10.98 and its 200-day simple moving average is $12.49.

Insider Transactions at Immunome

In other news, CTO Philip Tsai acquired 21,000 shares of the company's stock in a transaction dated Thursday, November 21st. The shares were bought at an average price of $9.43 per share, with a total value of $198,030.00. Following the purchase, the chief technology officer now owns 21,000 shares of the company's stock, valued at approximately $198,030. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Clay B. Siegall bought 66,057 shares of Immunome stock in a transaction that occurred on Thursday, November 21st. The shares were acquired at an average price of $9.54 per share, with a total value of $630,183.78. Following the completion of the acquisition, the chief executive officer now directly owns 485,693 shares of the company's stock, valued at $4,633,511.22. This represents a 15.74 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 252,862 shares of company stock valued at $2,140,545. Corporate insiders own 8.60% of the company's stock.

Hedge Funds Weigh In On Immunome

Institutional investors and hedge funds have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. grew its position in Immunome by 217.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company's stock worth $6,469,000 after acquiring an additional 302,916 shares in the last quarter. Victory Capital Management Inc. raised its holdings in Immunome by 48.1% during the third quarter. Victory Capital Management Inc. now owns 730,785 shares of the company's stock valued at $10,684,000 after buying an additional 237,497 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Immunome by 13.6% in the third quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company's stock worth $17,657,000 after buying an additional 144,557 shares during the last quarter. Magnus Financial Group LLC lifted its position in shares of Immunome by 107.8% in the fourth quarter. Magnus Financial Group LLC now owns 53,536 shares of the company's stock worth $569,000 after buying an additional 27,777 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its stake in shares of Immunome by 22.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 470,647 shares of the company's stock worth $6,881,000 after acquiring an additional 85,580 shares in the last quarter. Hedge funds and other institutional investors own 44.58% of the company's stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.